Cardiovascular Disease & Dyslipidemia

Citation model. Claims grounded in AllNutrition's trust-scored library carry an inline bracketed reference [n] linking to the References section, which lists each source's evidence level and AllNutrition trust score (0–1). Where an AllNutrition query returned an overall evidence_strength and consensus_level, those labels are surfaced in the Evidence Review so readers can calibrate confidence. Only sources actually returned by the tool are cited; no trust scores are invented.

---

1. Introduction

Atherosclerotic cardiovascular disease (ASCVD) remains the leading cause of death worldwide, and no other chronic disease has a nutrition evidence base as deep or as triangulated at the level of the low-density lipoprotein (LDL) particle. Randomized trials, prospective cohorts, and Mendelian randomization converge on one causal chain: apolipoprotein B (apoB)–containing lipoproteins are necessary and sufficient to cause atherosclerosis, and cumulative lifetime exposure — not a single blood draw — determines risk. Cardiovascular nutrition is simultaneously home to some of the most persistent public controversies: the alcohol J-curve, the egg/dietary-cholesterol saga, and the gap between LDL-lowering (a surrogate) and actually preventing myocardial infarction, stroke, and cardiovascular death (hard outcomes).

This module traces the causal chain from the vessel wall outward — how endothelial dysfunction and lipoprotein retention initiate atherosclerosis, how strong the LDL/apoB causal evidence is, and which dietary patterns and nutrients modify risk, through which endpoints. Students will practice the Module 1 discipline explicitly: distinguishing an LDL-lowering claim from a myocardial-infarction-prevention claim, and separating triangulated conclusions (saturated fat substitution, the Mediterranean diet, sodium reduction) from genuinely contested ones (the alcohol J-curve, moderate egg intake).

2. Learning Objectives

By the end of this module, the learner will be able to:

1. Describe the mechanistic sequence of atherosclerosis — endothelial dysfunction, apoB retention, oxidation, foam cell formation, plaque rupture — and the "response-to-retention" model.
2. Explain why apoB/particle number, rather than LDL-C mass, is the more accurate causal metric, per Mendelian randomization.
3. Quantify dose-response effects of saturated/trans fat, fiber, plant sterols, and dietary cholesterol on LDL-C/apoB, distinguishing surrogate from hard-outcome evidence.
4. Critically appraise Mediterranean diet (PREDIMED), DASH, fiber, nuts, and whole-grain evidence for CVD risk reduction, with effect sizes and certainty.
5. Explain sodium–BP–CVD causality, the alcohol J-curve resolved by Mendelian randomization, and divergent omega-3 trial results (REDUCE-IT vs. STRENGTH/VITAL).
6. Distinguish triglycerides/remnant cholesterol and Lp(a) as residual-risk markers with different diet-modifiability.
7. Apply secondary-prevention nutrition strategies and recognize diet–drug interactions in cardiovascular pharmacotherapy.

3. Scientific Foundations

3.1 Atherosclerosis pathobiology: endothelial dysfunction and apoB-lipoprotein retention

Atherosclerosis begins with endothelial dysfunction: hypertension, smoking, and hyperglycemia impair nitric oxide production and raise reactive oxygen species, increasing vascular permeability and adhesion-molecule expression (VCAM-1, ICAM-1) [1][2]. Through this compromised barrier, apoB-containing lipoproteins (chiefly LDL, but also VLDL/IDL remnants) infiltrate the subendothelial space and bind arterial wall proteoglycans. The "response-to-retention" model holds that lifetime apoB exposure, not a single measurement, drives plaque development [1]. Retained particles oxidize to oxLDL, recruiting monocytes that become cholesterol-laden foam cells; smooth muscle cells then form a fibrous cap over a necrotic lipid core, which inflammation and matrix metalloproteinases can degrade, precipitating plaque rupture [1]. Intensive LDL-lowering to ~1.8 mmol/L (70 mg/dL) stabilizes plaques, but residual risk from vascular inflammation and Lp(a) commonly persists [1]. A Cardiovascular-Kidney-Metabolic (CKM) paradigm frames visceral adiposity, insulin resistance, and kidney disease as amplifiers of this process [3].

3.2 LDL/apoB causality: the lipid hypothesis and Mendelian randomization

Triangulated RCT, cohort, and Mendelian randomization (MR) evidence now strongly supports LDL causality. MR studies find each SD increase in genetically predicted VLDL, IDL, or LDL confers a nearly identical ~60% increase in coronary risk regardless of particle type [4]. When modeled together adjusting for apoB, subfraction-specific associations attenuate toward zero, supporting a "particle burden" model: total particle number (apoB), not cholesterol mass, determines risk [4][5] — clinically relevant for "discordant" patients (e.g., insulin resistance with normal LDL-C but elevated apoB) [4]. Lipoprotein(a) [Lp(a)] is established by MR as an independent, causal risk factor for ASCVD and aortic stenosis; being 70–90% genetically determined, it is a largely diet-resistant residual-risk driver (Section 3.9) [4].

3.3 Dietary determinants of LDL/apoB: saturated fat, trans fat, dietary cholesterol

Saturated fat (SFA) dose-dependently raises LDL-C/apoB — trials doubling SFA from ~7–9% to 14–18% of energy significantly raised LDL-C [6]. Replacing SFA with unsaturated fat, carbohydrate, or protein cuts cardiovascular events by an estimated 21% [6]. Food source and chain length matter: SFA from red meat/butter carries higher risk than SFA from cheese, yogurt, or fish (plausibly a food-matrix effect), and longer-chain SFAs (C12–C18) are more consistently risk-linked than short/medium- or very-long-chain SFAs [6][10]. MUFA-enriched (oleic acid) diets show modest LDL-C reductions (~0.11 mmol/L) [9].

Trans fat carries an unambiguous, larger signal: it raises LDL-C while lowering HDL-C, and eliminating partially hydrogenated oils is associated with reduced population CVD mortality, particularly in older adults [5][38] — among the most settled findings in this field.

Dietary cholesterol, historically conflated with SFA, has weaker evidence: a crossover trial of 14 eggs/week for 5 weeks found no LDL-C elevation, concluding saturated fat — not cholesterol per se — drives LDL-C change [8]. Cholesterol absorption efficiency varies (~20–80%), so a "hyper-responder" subset sees larger rises, but guidelines (AHA, US DGA, Australian Heart Foundation) now generally permit ~1 egg/day; one postmenopausal cohort did find a modest association with IHD/stroke, so the picture is not fully settled [36].

Soluble fiber and plant sterols/stanols inhibit intestinal cholesterol absorption: 2 g/day of sterols/stanols lowers LDL-C ~8–10% (high-certainty), with no direct trial evidence yet of event reduction [26]. Pulses (~130 g/day) produce smaller LDL-C/apoB reductions [27]. The Portfolio Diet (plant protein, fiber, sterols, nuts) achieves ~17% LDL-C/15% apoB reduction in RCT meta-analysis, matching a whole-food plant-based (WFPB) diet in familial hypercholesterolemia (18% LDL-C reduction, 11.9% relative 10-year risk reduction) [28].

3.4 The Mediterranean diet: PREDIMED and hard-outcome trial evidence

PREDIMED is the most influential CVD-prevention nutrition RCT: in ~7,450 high-risk participants, a Mediterranean diet with olive oil or nuts reduced nonfatal MI/stroke/CV death versus a low-fat diet (confirmed HR 0.65 after re-analysis; per-protocol HR 0.42 in high adherers) [11]. CORDIOPREV replicated the direction (HR 0.72–0.75) [11]. A meta-analysis of 19 studies (>91,000 participants) found higher adherence reduced MACE/mortality in established CVD, with moderate-certainty cohort evidence plus RCT support, even though blood pressure, lipid, and body-composition effects were inconsistent [15][14]. Notably, the MACE/mortality benefit is not fully explained by lipid-surrogate change, implying added mechanisms — inflammation, endothelial function, gut metabolites [12][13].

3.5 DASH, dietary fiber, nuts, and whole grains

DASH improves multiple risk factors in RCT meta-analysis, with dietary nitrate driving substantial blood-pressure reduction [39]. Causal-inference comparisons suggest the Mediterranean diet may show a stronger, more consistent mortality benefit, plausibly because DASH's benefit concentrates on blood pressure alone [39]. Fiber shows a consistent dose-response: each +10 g/day is linked to 18% lower all-cause and 24% lower cardiovascular mortality (NHANES), with whole-grain fiber showing 15–32% CVD mortality reduction [16][17], via bile-acid binding, reduced CRP, improved insulin sensitivity, and SCFA production [16]. Whole grains replacing refined grains show 19–22% lower CVD/CHD incidence and 15–32% lower mortality in a GRADE RCT review, though the same review found insufficient RCT evidence for lipid-surrogate improvement — cohort signal outrunning short-term trial data [18]. Nuts show a 28–31% reduction in major events (PREDIMED nut arm and meta-analyses), plus improved lipids, ~19% lower hypertension risk, and lower metabolic syndrome prevalence [37].

3.6 Sodium and the link to hypertension

Sodium–blood pressure is linear and dose-dependent (~1,850–5,230 mg/day), and rigorously measured (24-h urine) sodium–CVD associations are also linear, not J-shaped — apparent J-curves in weaker studies reflect measurement artifact and reverse causation [33][34]. Population sodium-reduction programs lower systolic BP ~2.6 mmHg, and TOHP showed reduced events 10–15 years post-intervention [33]. Targets range <2,000 mg/day (WHO/NASEM) to <1,500 mg/day (AHA, hypertensive), against typical intakes of 3,400–4,300 mg/day [33].

3.7 Alcohol and cardiovascular disease: the J-curve controversy

Observational cohorts report a J-shaped alcohol–CVD relationship, but MR substantially undermines causality: genetic variants reducing consumption associate with lower risk across the exposure range, consistent with the sick-quitter effect inflating apparent "protection" among abstainers [19]. MR also links alcohol to worse hypertension, insulin resistance, and lipids [19]. Guidance is age-stratified: under 35, no MR-supported benefit exists and abstinence is advised; over 50, moderate meal-associated drinking is framed as harm reduction pending the ongoing UNATI RCT (post-2028), not an endorsement [19] — a clean case for weighting MR over confounded cohort data.

3.8 Coffee, tea, and sugar-sweetened beverages

Tea may have prevented ~15.5% of global IHD cases and 8.3% of IHD deaths in 2021, via flavan-3-ols/flavonols improving endothelial function [21]. Coffee shows favorable, dose-dependent mortality effects (lowest risk ~3.5 cups/day) with no general-population AF risk, though ≥4 cups/day may worsen outcomes in established heart failure via caffeine's hemodynamic effects [22]. Sugar-sweetened beverages (SSBs) show dose-dependent CVD, hypertension, and mortality associations; the highest UK Biobank sugar-beverage quartile carried a 16% higher mortality hazard, with BMI mediating only ~37% of the SSB–hypertension link — implying non-adiposity harm via fructose-driven triglyceride/LDL and inflammatory effects [23][24].

3.9 Triglycerides, remnant cholesterol, and lipoprotein(a)

Triglyceride-rich remnants (VLDL/IDL) are independently atherogenic, driving residual risk even at goal LDL-C; remnant cholesterol improves risk discrimination and correlates with arterial stiffness via inflammation [25]. Diet strongly modifies triglycerides — refined sugar raises them; unsaturated-fat substitution can lower them ~29% [25]. Lp(a), by contrast, is ~70–90% genetically determined; this module's repeated direct queries on diet-and-Lp(a) returned no usable synthesis (server errors) — a genuine gap, not a claim. Lifestyle counseling has limited utility for Lp(a); optimizing other modifiable contributors is the mainstay.

3.10 Omega-3 fatty acids and surrogate-vs-hard-outcome divergence

Omega-3 evidence exemplifies trial-design sensitivity (cross-reference Module 5). Meta-analyses show ~13% lower MI risk and ~9% lower CHD mortality, with 45% lower sudden cardiac death in the lower-dose GISSI-Prevenzione trial [29][30]. Yet REDUCE-IT (4 g/day purified EPA) showed 25% MACE reduction while STRENGTH/VITAL (mixed EPA+DHA, lower doses) were neutral — plausibly reflecting EPA-specific effects, REDUCE-IT's mineral-oil comparator versus STRENGTH's corn oil, dose, and REDUCE-IT's high-triglyceride, high-risk population [30]. High-dose omega-3 (≥1.5–4 g/day) also carries dose-dependent atrial fibrillation risk [29].

3.11 Secondary prevention and diet–drug interactions

Mediterranean diet adherence shows the largest, most consistent secondary-prevention MACE/mortality reduction; the EAT-Lancet pattern trends toward reduced non-fatal events pending RCT confirmation [15][31]. AHA's 2026 statement on cardiac malnutrition/cachexia cautions against overly restrictive counseling that risks malnutrition in vulnerable patients [31].

Key diet–drug interactions: grapefruit juice inhibits CYP3A4, raising myopathy risk with atorvastatin/simvastatin/lovastatin; warfarin requires consistent (not restricted) vitamin K, with hibiscus tea, green tea, and herbals (St. John's Wort, ginkgo, garlic) able to shift INR either direction; omega-3s potentiate bleeding risk with antiplatelets/anticoagulants; red yeast rice (monacolin K) should never be combined with prescribed statins [32][25].

4. Clinical Relevance

Cardiovascular disease is where nutrition counseling most directly intersects with pharmacotherapy, and where the surrogate-versus-hard-outcome distinction has the highest stakes: a clinician who conflates "lowers LDL-C" with "prevents heart attacks" may over-promise benefit from surrogate-level evidence alone (e.g., isolated phytosterol supplementation), while one who dismisses diet because "only drugs move hard outcomes" ignores robust, trial-level Mediterranean-diet and sodium-reduction data. Physicians must also screen for diet–drug interactions (grapefruit-statin, vitamin K–warfarin, fish-oil–antiplatelet) and correct common misconceptions patients bring from lay media (the alcohol J-curve, "eggs are dangerous") using the strength-calibrated language modeled in Module 1.

5. Evidence Review

Established (high confidence):

• ApoB-containing lipoprotein retention causally drives atherosclerosis; apoB/particle number outperforms LDL-C mass as the MR-supported causal metric. evidence_strength: moderate, consensus_level: moderate [1][4].
• Saturated fat raises LDL-C/apoB dose-dependently; replacing SFA with unsaturated fat cuts cardiovascular events (~21% relative reduction). evidence_strength: strong, consensus: moderate [6].
• The Mediterranean diet (PREDIMED, CORDIOPREV, secondary-prevention meta-analyses) reduces MACE and cardiovascular mortality, trial and cohort evidence converging. evidence_strength: strong, consensus: high [11][15].
• Sodium reduction lowers blood pressure linearly, and rigorously measured (24-h urine) sodium–CVD associations are linear, not J-shaped. evidence_strength: strong, consensus: moderate [33][34].
• SSB intake increases CVD, hypertension, and all-cause mortality dose-dependently. evidence_strength: moderate, consensus: moderate [23][24].

Probable:

• Fiber and whole grains reduce cardiovascular/all-cause mortality dose-dependently, though RCT evidence for whole-grain effects on lipid surrogates remains limited despite a strong cohort/hard-outcome signal. evidence_strength: strong, consensus: moderate [16][18].
• Nuts, the Portfolio Diet, and plant sterols/stanols meaningfully lower LDL-C/apoB; nuts additionally show cohort-level MACE reduction. evidence_strength: strong/moderate, consensus: moderate [26][28][37].
• Alcohol's apparent cardioprotection is not causal — MR indicates increased risk across the consumption range, contradicting the observational J-curve. evidence_strength: moderate, consensus: moderate [19].
• Moderate egg/cholesterol intake (~1/day) does not meaningfully raise LDL-C for most people, though hyper-responders and some cohort signals complicate a uniform conclusion. evidence_strength: strong, consensus: moderate [8][36].

Emerging:

• The mechanistic basis for divergent omega-3 trial results (REDUCE-IT vs. STRENGTH/VITAL) — EPA-specific effects, comparator, dose, population selection. evidence_strength: strong, consensus: moderate [29][30].
• Remnant cholesterol as an independent, diet-modifiable residual-risk marker beyond LDL-C. evidence_strength: moderate, consensus: moderate [25].

Controversial:

• Whether small, dense LDL is more atherogenic per particle than large, buoyant LDL, versus apoB/particle number as the only metric that matters; broader "cholesterol hypothesis" skepticism in some narrative reviews. evidence_strength: moderate, consensus: mixed [5][6][7].
• The clinical meaningfulness of a moderate-alcohol "Mediterranean drinking pattern" for adults over 50, pending the UNATI RCT. evidence_strength: moderate, consensus: mixed [19].

Unsupported / overstated:

• That diet can produce clinically meaningful Lp(a) reductions; Lp(a) is almost entirely genetically determined, and this module's direct diet-and-Lp(a) queries returned no usable synthesis — a gap, not a sourced claim [4].
• Treating "seed oils are toxic" or a blanket LDL-causality "denial" position as consensus; the narrative reviews raising these concerns carry lower trust scores than the systematic reviews/MR studies supporting LDL/apoB causality [5][6].

6. Practical Clinical Applications

Dietary strategies, roughly in order of evidentiary strength:

1. Mediterranean-pattern eating (olive oil, nuts, legumes, fish, vegetables, limited red/processed meat) as first-line counseling for both primary and secondary prevention — the strongest hard-outcome trial evidence [11][15].
2. Sodium reduction toward <2,300 mg/day (<1,500 mg/day if hypertensive) — high-certainty blood-pressure and downstream CVD-risk intervention [33].
3. Substituting saturated with unsaturated fat (olive oil, nuts, fatty fish) rather than refined carbohydrate, which does not reliably confer benefit and may raise triglycerides [6][25].
4. Increasing soluble fiber, plant sterols/stanols, and pulses (Portfolio Diet approach) as add-on LDL-lowering, useful when reducing statin dose or when statins are not tolerated [26][27][28].
5. Eliminating trans fat — the least controversial recommendation in this module [5][38].
6. Moderating SSBs and added sugar, given dose-dependent CVD/mortality associations independent of BMI [23][24].

When (and when not) to counsel:

• Egg/cholesterol restriction is not indicated for most patients; reserve for known hyper-responders or LDL-C persistently above goal despite saturated-fat reduction [8][36].
• Never recommend initiating alcohol for cardioprotection; for existing moderate drinkers over 50, frame current guidance as harm reduction, not endorsement, pending RCT data [19].
• Reserve pharmacologic-dose EPA for elevated-triglyceride, high-background-risk patients (REDUCE-IT population); routine mixed EPA+DHA in average-risk patients lacks consistent MACE benefit and carries an AF signal [29][30].
• For elevated Lp(a), optimize modifiable contributors (LDL-C, blood pressure, smoking) rather than promising dietary Lp(a) reduction [4].

Nutrition–drug interaction checklist: grapefruit juice with CYP3A4-metabolized statins (atorvastatin, simvastatin, lovastatin); consistent (not restricted) vitamin K with warfarin, flagging hibiscus tea and interacting herbals (St. John's Wort, ginkgo, garlic); high-dose fish oil (≥4 g/day) with antiplatelet/anticoagulant therapy; never combine red yeast rice with prescribed statins [32][25].

7. Clinical Pearls

• "ApoB, not LDL-C" — when discordant, apoB is the better-supported causal metric, especially with insulin resistance or diabetes.
• A PREDIMED hazard ratio is a trial-level effect on hard outcomes; a phytosterol trial's LDL-C drop is a surrogate effect. Both matter but answer different questions.
• The alcohol J-curve is a textbook case of confounding by indication (sick-quitter effect), unmasked by Mendelian randomization.
• Trans fat elimination is as close to a "free win" as cardiovascular nutrition offers.
• Lp(a) is the lipid parameter diet cannot fix — don't over-promise.
• REDUCE-IT vs. STRENGTH shows how comparator, dose, formulation, and population selection can make two omega-3 trials look contradictory.

8. Common Misconceptions

• "Dietary cholesterol and eggs are dangerous for the heart." Saturated fat, not dietary cholesterol, is the primary lipid-raising lever for most people; up to ~1 egg/day is compatible with major guidelines [8][36].
• "A glass of wine a day protects your heart." Rests on confounded observational data; Mendelian randomization does not support a causal cardioprotective effect at any level [19].
• "All omega-3 trials failed, so fish oil doesn't work." Results are formulation-, dose-, and population-dependent; purified high-dose EPA in high-triglyceride, high-risk patients (REDUCE-IT) showed benefit where lower-dose mixed EPA+DHA in average-risk populations (VITAL, STRENGTH) did not [29][30].
• "Small, dense LDL is the real danger; large LDL is harmless." Multivariable MR indicates apoB/particle number, not particle size, dominates risk [4][5].
• "If LDL-C drops, risk drops proportionally, for any intervention." The Mediterranean diet reduces MACE substantially even in trials without significant LDL-C or BP change — benefit is not fully mediated by lipid surrogates [15].

9. Summary

Atherosclerosis is initiated by endothelial dysfunction and driven causally by cumulative retention of apoB-containing lipoproteins in the arterial wall — a conclusion robustly supported by Mendelian randomization, trial, and cohort data, with apoB/particle number outperforming LDL-C mass as the operative metric. Saturated and trans fat raise LDL-C/apoB dose-dependently; soluble fiber, plant sterols, pulses, and whole-food plant-based patterns lower them; dietary cholesterol itself is a comparatively minor lever for most people. The Mediterranean diet has the strongest hard-outcome trial evidence of any dietary pattern, with benefits extending beyond its modest effects on lipid surrogates. Sodium reduction, fiber, nuts, and whole grains show dose-dependent risk reduction; sugar-sweetened beverages show dose-dependent harm. The alcohol J-curve is a paradigm case of observational confounding resolved by genetic evidence, and the divergent omega-3 trials illustrate how formulation, dose, comparator, and population selection can make apparently contradictory RCTs both be "correct." Triglycerides and remnant cholesterol are diet-modifiable residual-risk markers; lipoprotein(a) is not. Clinicians should counsel Mediterranean-pattern eating, sodium moderation, fat-quality substitution, and fiber/plant-sterol strategies as primary tools, while remaining alert to diet–drug interactions (grapefruit-statins, vitamin K-warfarin, fish oil-antiplatelets) in patients on cardiovascular pharmacotherapy.

10. References

Ordered by evidence strength / relevance. Evidence level and AllNutrition trust score (0–1) as returned by the tool.

1. Emerging biomedical and pharmaceutical strategies for the treatment of atherosclerosis: from conventional lipid-lowering therapy to nanomedicine. Journal of Applied Biomedicine (2026). Review — trust 0.833.
2. Endothelial dysfunction is a risk factor for lipid metabolism disorders: underlying mechanisms and potential treatments. Microvascular Research (2026). Review — trust 0.713.
3. Atherosclerosis as an evolutionary mismatch disease: from ancestral biology to cardiometabolic vulnerability. Current Problems in Cardiology (2026). Review — trust 0.762.
4. Association of the Discordance Between Apolipoprotein B and Low-Density Lipoprotein Cholesterol With Cognition. Journal of the American Heart Association (2026). Observational — trust 0.625.
5. Concerns about the health effects of industrially produced seed oils are without scientific foundation: a scoping narrative review. Critical Reviews in Food Science and Nutrition (2026). Review — trust 0.637.
6. Fatty Acids and Their Roles in Cardiac Physiology and Pathology: Mechanistic and Interventional Studies. Nutrients (2026). Review — trust 0.715.
7. Re-evaluating Cardiovascular Risk: A Narrative Review Challenging the Cholesterol Hypothesis and Identifying Modern Dietary Drivers. Cureus (2026). Review — trust 0.633.
8. Reply to Letter to the Editor [dietary cholesterol / egg feeding trial]. The American Journal of Clinical Nutrition (2025). Review — trust 0.765.
9. The effect of oleic acid enriched diets on glucose and lipid metabolism: a systematic review and meta-analysis. Nutrition & Metabolism (2026). Systematic review — trust 0.857.
10. Fatty Acids and Their Roles in Cardiac Physiology and Pathology. Nutrients (2026). Review — trust 0.715. (chain-length/food-source findings)
11. The Mediterranean diet and cardiovascular disease. Cardiovascular Research (2025). Review — trust 0.77.
12. Inflammation and Chronic Disease: The Mediterranean Diet in Precision and Personalized Nutrition. Annals of Nutrition and Metabolism (2026). Review — trust 0.742.
13. Diet, the protective bridge connecting nutrition and cardiovascular health: A review. Food Chemistry: X (2026). Review — trust 0.73.
14. Effectiveness of Mediterranean diet for the primary prevention of cardiovascular diseases: A systematic review and meta-analysis featured in the Italian National Guidelines. Nutrition (2025). Systematic review — trust 0.857.
15. Efficacy of Mediterranean diet for the prevention of cardiovascular disease in patients: A systematic review and meta-analysis featured in the Italian National Guidelines. Nutrition (2025). Systematic review — trust 0.883.
16. Effectiveness of High-Fiber, Plant-Based Diets in Reducing Cardiovascular Risk Factors Among Middle-Aged and Older Adults: A Systematic Review. Cureus (2024). Systematic review — trust 0.797.
17. Association between dietary fiber intake and mortality in populations with accelerated biological aging: NHANES 1999–2018. Journal of Clinical Biochemistry and Nutrition (2026). Observational — trust 0.732.
18. The Effect of Replacing Refined Grains with Whole Grains on Cardiovascular Risk Factors: A Systematic Review and Meta-Analysis of RCTs with GRADE Clinical Recommendation. Journal of the Academy of Nutrition and Dietetics (2020). Systematic review — trust 0.79.
19. The Mediterranean diet and cardiovascular disease (alcohol/J-curve/UNATI trial discussion). Cardiovascular Research (2025). Review — trust 0.77.
20. Trends in the Co-Occurrence of Alcohol Use and Cardiovascular Disease Among U.S. Adults, 1999 to 2023. JACC: Advances (2026). Observational — trust 0.812.
21. Tea intake as a dietary factor for cardiovascular health: global estimates of potentially preventable ischemic heart disease. Nutrition Journal (2026). Observational — trust 0.732.
22. The Impact of Coffee Consumption on Mortality Among Patients With Heart Failure. Cureus (2026). Review — trust 0.633.
23. Sugar-sweetened beverage consumption and risk of premature coronary artery disease in a multi-ethnic Iranian case–control study. Nutrition & Metabolism (2025). Observational — trust 0.762.
24. Intake of Added Sugar from Different Sources and Risk of All-Cause Mortality and Cardiovascular Diseases: The Role of Body Mass Index. The Journal of Nutrition (2024). Observational — trust 0.76.
25. Unmasking residual cardiovascular risk: the paradoxical interaction between remnant cholesterol and calculated LDL-C in a tertiary-care cohort. Lipids in Health and Disease (2026). Observational — trust 0.732.
26. Efficacy of phytosterols for reduction of cardiometabolic risk factors: An umbrella review of systematic reviews and meta-analyses and updated dose-response meta-analyses of RCTs. Clinical Nutrition (2026). Review — trust 0.775.
27. Effect of Different Types of Whole Dietary Pulses on Established Therapeutic Lipid Targets for Cardiovascular Risk Reduction: An Updated Systematic Review and Dose–Response Meta-Analysis of RCTs. Journal of the American Heart Association (2026). Systematic review — trust 0.892.
28. Impact of a whole food, plant-based diet on LDL-cholesterol and cardiovascular risk factors in adults with heterozygous familial hypercholesterolemia: a randomized, crossover, fully controlled feeding trial. Nature Communications (2026). RCT — trust 0.853.
29. Meta-Analysis of DHA and EPA Supplementation on Cardiovascular Outcomes and Atrial Fibrillation Risk. Pharmacology Research & Perspectives (2026). Systematic review — trust 0.827.
30. Global burden of ischemic heart disease due to omega-3 deficiency: 204-country analysis, 1990–2021. Frontiers in Nutrition (2025). Observational — trust 0.767.
31. Malnutrition and Cachexia in Inpatients With Acute Cardiac Conditions: A Scientific Statement From the American Heart Association. Circulation (2026). Guideline — trust 0.917.
32. Food-drug interactions of novel drugs used in cardiologic and diabetic patients – a PRISMA scoping review. Frontiers in Pharmacology (2026). Review — trust 0.73.
33. Rethinking the Impact of Dietary Sodium and Potassium on Blood Pressure to Advance Public Health. The American Journal of Clinical Nutrition (2026). Review — trust 0.777.
34. Pathophysiological Mechanisms and Clinical Controversies of Sodium-Induced Hypertension: A Multi-Systemic Perspective. Nutrients (2026). Review — trust 0.85.
35. The Dietary Management Of Sodium In Children With Kidney Diseases — Clinical Practice Recommendations From The Pediatric Renal Nutrition Taskforce. Pediatric Nephrology (2025). Guideline — trust 0.907.
36. Eggs as a Nutrient-Rich Food with Potential Relevance to Sleep, Metabolic Health, and Well-Being During the Menopausal Transition: A Narrative Review. Nutrients (2025). Review — trust 0.685.
37. A perspective on vegetarian dietary patterns and risk of metabolic syndrome. British Journal of Nutrition (2014). Review — trust 0.90.
38. Impact of diets high in trans-fatty acids on cardiovascular diseases in adults aged 55 and older: insights from the Global Burden of Disease 2021 data. Frontiers in Nutrition (2026). Observational — trust 0.767.
39. Effects of the Dietary Approach to Stop Hypertension (DASH) diet on cardiovascular risk factors: a systematic review and meta-analysis. British Journal of Nutrition (2015). Systematic review — trust 0.682; supplemented by Causal Inference Framework Reveals Mediterranean Diet Superiority and Inflammatory Mediation Pathways in Mortality Prevention: A Comparative Analysis of Nine Common Dietary Patterns. Foods (2025). Observational — trust 0.732.

Supporting sources also surfaced: Gene–diet interactions and lipid profiles, Curr Issues Mol Biol (2026), systematic review, trust 0.762; The relationship between the EAT-Lancet dietary pattern and risk of cardiovascular events in patients with established CVD, Eur J Nutr (2025), observational, trust 0.752; The Role of Omega-3 and Omega-6 PUFA Supplementation in Human Health, Foods (2025), review, trust 0.695; Bioactive Natural Products in Cardiovascular Disease: Focus on Thrombotic Events, Phytotherapy Research (2026), review, trust 0.588; Possible Interaction Between Hibiscus and Warfarin Resulting in Severe INR Elevation, Cureus, observational, trust 0.562. Dietary intervention effects on lipoprotein(a) were queried directly but AllNutrition returned no usable synthesis (repeated server errors); this is flagged as an evidence gap rather than a sourced claim.